USPSTF screening recommendation could lead to greater numbers of avoidable deaths

Nature Reviews Urology

Volumn 11, Issue 9, 2014, Pages 481-

  Fenner, Annette ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; BIOLOGICAL MARKER;

CANCER GROWTH; CANCER INCIDENCE; CANCER MORTALITY; CANCER PATIENT; CANCER SCREENING; CANCER SPECIFIC SURVIVAL; CONSERVATIVE TREATMENT; HUMAN; MALE; METASTASIS; NOTE; PRIORITY JOURNAL; PROSTATE CANCER; UNITED STATES; ADVISORY COMMITTEE; ARTICLE; BLOOD; EARLY DIAGNOSIS; PROSTATE TUMOR; RANDOMIZED CONTROLLED TRIAL (TOPIC); STANDARD;

ADVISORY COMMITTEES; BIOLOGICAL MARKERS; EARLY DETECTION OF CANCER; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; UNITED STATES;

EID: 84908087797     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2014.209     Document Type: Note

References (3)

1. Gulati, R. et al. Expected population impacts of discontinued prostate-specific antigen screening. Cancer doi:10.1002/cncr.28932
2. Reinhardt, D. & Catalona, W. Prostate cancer: The growing evidence supporting mid-life PSA testing. Nat. Rev. Urol. 10, 436-438 (2013)
3. Hoag, N. A. & Goldenberg, S. L. Prostate cancer in 2012: Paradigm shifts in prostate cancer diagnosis and treatment. Nat. Rev. Urol. 10, 69-70 (2013)